Literature DB >> 33711331

Sulforaphane inhibits NLRP3 inflammasome activation in microglia through Nrf2-mediated miRNA alteration.

Kemal Ugur Tufekci1, Ilkcan Ercan2, Kamer Burak Isci3, Melis Olcum4, Bora Tastan2, Ceren Perihan Gonul2, Kursad Genc5, Sermin Genc6.   

Abstract

The NLRP3 inflammasome is a multiprotein complex that activates caspase-1 and triggers the release of the proinflammatory cytokines IL-1β and IL-18 in response to diverse signals. Although inflammasome activation plays critical roles against various pathogens in host defense, overactivation of inflammasome contributes to the pathogenesis of inflammatory diseases, including acute CNS injuries and chronic neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease. In the current study, we demonstrated that Sulforaphane (SFN), a dietary natural product, inhibits NLRP3 inflammasome mediated IL-1β and IL-18 secretion and pyroptosis in murine microglial cells. SFN decreased the secretion of IL-1β and IL-18, and their mRNA levels in LPS primed microglia triggered by ATP. SFN suppressed the overexpression of cleaved caspase-1 and NLRP3 protein expressions as measured by caspase activity assay and western blot, respectively. SFN also prevented caspase-1 dependent pyroptotic cell death in microglia. Our data indicate that SFN suppresses NLRP3 inflammasome via the inhibition of NF-κB nuclear translocation and Nrf2 mediated miRNAs expression modulation in murine microglia.
Copyright © 2021. Published by Elsevier B.V.

Entities:  

Keywords:  Microglia; NLRP3 inflammasome; Nrf2; Pyroptosis; Sulforaphane; microRNA

Mesh:

Substances:

Year:  2021        PMID: 33711331     DOI: 10.1016/j.imlet.2021.03.004

Source DB:  PubMed          Journal:  Immunol Lett        ISSN: 0165-2478            Impact factor:   3.685


  8 in total

1.  Resveratrol Inhibits NLRP3 Inflammasome-Induced Pyroptosis and miR-155 Expression in Microglia Through Sirt1/AMPK Pathway.

Authors:  Kemal Ugur Tufekci; Bedir Irem Eltutan; Kamer Burak Isci; Sermin Genc
Journal:  Neurotox Res       Date:  2021-11-05       Impact factor: 3.911

Review 2.  The Role of the NLRP3 Inflammasome in Mediating Glomerular and Tubular Injury in Diabetic Nephropathy.

Authors:  B M Williams; C L Cliff; K Lee; P E Squires; C E Hills
Journal:  Front Physiol       Date:  2022-06-09       Impact factor: 4.755

Review 3.  Use of sulforaphane in COVID-19: Clinical trials are needed.

Authors:  Chia Siang Kow; Dinesh Sangarran Ramachandram; Syed Shahzad Hasan
Journal:  Mol Immunol       Date:  2022-03-07       Impact factor: 4.407

Review 4.  The Role of NLRP3 Inflammasome in Alzheimer's Disease and Potential Therapeutic Targets.

Authors:  Tao Liang; Yang Zhang; Suyuan Wu; Qingjie Chen; Lin Wang
Journal:  Front Pharmacol       Date:  2022-02-16       Impact factor: 5.810

5.  Sulforaphane Modulates the Inflammation and Delays Neurodegeneration on a Retinitis Pigmentosa Mice Model.

Authors:  Antolín Canto; Javier Martínez-González; María Miranda; Teresa Olivar; Inma Almansa; Vicente Hernández-Rabaza
Journal:  Front Pharmacol       Date:  2022-03-01       Impact factor: 5.810

Review 6.  Targeting NLRP3 Inflammasome With Nrf2 Inducers in Central Nervous System Disorders.

Authors:  Bora Tastan; Burak I Arioz; Sermin Genc
Journal:  Front Immunol       Date:  2022-03-28       Impact factor: 7.561

Review 7.  Microglia Pyroptosis: A Candidate Target for Neurological Diseases Treatment.

Authors:  Xian Wu; Teng Wan; Xiaoyu Gao; Mingyuan Fu; Yunfeng Duan; Xiangru Shen; Weiming Guo
Journal:  Front Neurosci       Date:  2022-07-22       Impact factor: 5.152

8.  Immunomodulatory Effects of (R)-Sulforaphane on LPS-Activated Murine Immune Cells: Molecular Signaling Pathways and Epigenetic Changes in Histone Markers.

Authors:  Manuel Alcarranza; Isabel Villegas; Rocío Muñoz-García; Rocío Recio; Inmaculada Fernández; Catalina Alarcón-de-la-Lastra
Journal:  Pharmaceuticals (Basel)       Date:  2022-08-04
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.